Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Onco
Special Issues
Liquid Biopsy and Peripheral Immune Status in Cancer Therapy Response
share announcement

Liquid Biopsy and Peripheral Immune Status in Cancer Therapy Response

A special issue of Onco (ISSN 2673-7523).

Deadline for manuscript submissions: 31 May 2026 | Viewed by 1196

Special Issue Editors

Dr. Galatea Kallergi

E-Mail Website
Guest Editor
Department of Biology, University of Patras, 26504 Patras, Greece
Interests: signal transduction pathways in metastasis; liquid biopsy, detection and characterization of CTCs
Special Issues, Collections and Topics in MDPI journals
Dr. Anastasia Xagara

E-Mail Website
Guest Editor
Laboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, GR-41110 Larissa, Greece
Interests: circulating tumor cells (CTCs); cancer
Dr. Constantin N. Baxevanis

E-Mail Website
Guest Editor
1. Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece
2. Flow Cytometry Unit, Section of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Ilisia, 15784 Athens, Greece
Interests: cancer immunology; cancer immunotherapy; biomarkers; precision oncology; immune resistance; cancer vaccines; immune escape; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The shift to personalized oncology has already enabled longer remission and overall survival periods for many cancer patients. The primary tumor is not always accessible or adequate for performing all available biomarker analyses for patient sub-classification. Moreover, due to the rapid development of novel therapeutic interventions, the need for accurate biomarkers should be prioritized. Additionally, cancer development and therapeutic response are complex, multifunctional processes. Therefore, it is starting to become clear that combinatorial biomarkers may offer more accurate diagnostic, prognostic, and predictive results.

This Special Issue on Liquid Biopsy and Peripheral Immune Status in Cancer Therapy Response will focus on the value of novel, easily accessible biomarkers in the response to all types of tumor therapy. We welcome submissions exploring the value of liquid biomarkers such as CTCs, exosomes, ctDNA, and blood immune cell populations.

Dr. Galatea Kallergi
Dr. Anastasia Xagara
Dr. Constantin N. Baxevanis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liquid biopsy
  • CTCs
  • exosomes
  • ctDNA
  • immune biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 921 KB  
Review
Pre-Existing Immunity Shapes Cancer Immunotherapy Efficacy
by Anastasia Xagara, Filippos Koinis, Konstantinos Tsapakidis, Ioannis Samaras, Evangelia Chantzara, Konstantina Vasilieva, Alexandros Lazarou, Vassilis Georgoulias and Athanasios Kotsakis
Onco 2026, 6(1), 4; https://doi.org/10.3390/onco6010004 - 7 Jan 2026
Viewed by 524
Abstract
Immunotherapy has revolutionized the management of patients with cancer. Immune checkpoint inhibition (ICI) is a promising treatment option that targets the molecular mechanisms that cancer cells exploit to prevent immune-mediated elimination. ICI therapy can cause exceptional long-term tumor remissions, in some cases, even [...] Read more.
Immunotherapy has revolutionized the management of patients with cancer. Immune checkpoint inhibition (ICI) is a promising treatment option that targets the molecular mechanisms that cancer cells exploit to prevent immune-mediated elimination. ICI therapy can cause exceptional long-term tumor remissions, in some cases, even after treatment discontinuation. Despite its success, many patients acquire resistance or fail to respond due to immune escape mechanisms mediated by the tumor and its microenvironment. Pre-existing immunity status of individuals seems to play a fundamental role in immunotherapy response and eventually tumor progression, as it orchestrates tumor-immune interactions. Different immune cell subsets, both in the tumor microenvironment and the peripheral blood, are established mediators that contribute to immune escape in various tumor types. Based on these findings, the elucidation of the mechanisms implicated in the regulation of these immune cells has become a priority for investigators focused on improving the efficacy of ICI. This will be essential for identifying responders as well as for developing novel therapeutic modalities to improve clinical outcomes. Herein, we summarize preclinical and clinical evidence proposing a predictive role of pre-existing immunity for clinical responses to immunotherapies. Full article
(This article belongs to the Special Issue Liquid Biopsy and Peripheral Immune Status in Cancer Therapy Response)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop